TOF Versus SOX in Metastatic Gastric Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

June 30, 2014

Conditions
Gastric Cancer
Interventions
DRUG

paclitaxel+oxaliplatin+fluorouracil

"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."

DRUG

oxaliplatin+S1

"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area \< 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER

NCT02442362 - TOF Versus SOX in Metastatic Gastric Cancer | Biotech Hunter | Biotech Hunter